| Oncogenically active MYD88 mutations in human lymphoma VN Ngo, RM Young, R Schmitz, S Jhavar, W Xiao, KH Lim, ... Nature 470 (7332), 115-119, 2011 | 1811 | 2011 |
| Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a … TM Nywening, A Wang-Gillam, DE Sanford, BA Belt, RZ Panni, ... The lancet oncology 17 (5), 651-662, 2016 | 750 | 2016 |
| Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis B Ancrile, KH Lim, CM Counter Genes & development 21 (14), 1714-1719, 2007 | 506 | 2007 |
| Toll-like receptor signaling KH Lim, LM Staudt Cold Spring Harbor perspectives in biology 5 (1), a011247, 2013 | 495 | 2013 |
| Activation of RalA is critical for Ras-induced tumorigenesis of human cells KH Lim, AT Baines, JJ Fiordalisi, M Shipitsin, LA Feig, AD Cox, CJ Der, ... Cancer cell 7 (6), 533-545, 2005 | 451 | 2005 |
| RALA and RALBP1 regulate mitochondrial fission at mitosis DF Kashatus, KH Lim, DC Brady, NLK Pershing, AD Cox, CM Counter Nature cell biology 13 (9), 1108-1115, 2011 | 407 | 2011 |
| Tumour maintenance is mediated by eNOS KH Lim, BB Ancrile, DF Kashatus, CM Counter Nature 452 (7187), 646-649, 2008 | 372 | 2008 |
| The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis YS Lee, KH Lim, X Guo, Y Kawaguchi, Y Gao, T Barrientos, P Ordentlich, ... Cancer research 68 (18), 7561-7569, 2008 | 329 | 2008 |
| Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells KH Lim, K O'Hayer, SJ Adam, SDS Kendall, PM Campbell, CJ Der, ... Current Biology 16 (24), 2385-2394, 2006 | 289 | 2006 |
| Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance KH Lim, CM Counter Cancer cell 8 (5), 381-392, 2005 | 238 | 2005 |
| Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a … A Cercek, T Boerner, BR Tan, JF Chou, M Gönen, TM Boucher, ... JAMA oncology 6 (1), 60-67, 2020 | 195 | 2020 |
| Pathogenetic importance and therapeutic implications of NF‐κB in lymphoid malignancies KH Lim, Y Yang, LM Staudt Immunological reviews 246 (1), 359-378, 2012 | 192 | 2012 |
| Tumor–stroma IL1β-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer D Zhang, L Li, H Jiang, Q Li, A Wang-Gillam, J Yu, R Head, J Liu, ... Cancer research 78 (7), 1700-1712, 2018 | 187 | 2018 |
| Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies A Teague, KH Lim, A Wang-Gillam Therapeutic advances in medical oncology 7 (2), 68-84, 2015 | 174 | 2015 |
| Beyond just a tight fortress: contribution of stroma to epithelial-mesenchymal transition in pancreatic cancer A Bulle, KH Lim Signal Transduction and Targeted Therapy 5 (1), 249, 2020 | 149 | 2020 |
| Aurora-A phosphorylates, activates, and relocalizes the small GTPase RalA KH Lim, DC Brady, DF Kashatus, BB Ancrile, CJ Der, AD Cox, ... Molecular and cellular biology 30 (2), 508-523, 2010 | 132 | 2010 |
| Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion H Jiang, X Liu, BL Knolhoff, S Hegde, KB Lee, H Jiang, RC Fields, ... Gut 69 (1), 122-132, 2020 | 123 | 2020 |
| Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? KH Lim, E Chung, A Khan, D Cao, D Linehan, E Ben-Josef, ... The oncologist 17 (2), 192-200, 2012 | 110 | 2012 |
| Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment H Sun, S Cao, RJ Mashl, CK Mo, S Zaccaria, MC Wendl, SR Davies, ... Nature communications 12 (1), 5086, 2021 | 99 | 2021 |
| Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA AO Kaseb, NS Sánchez, S Sen, RK Kelley, B Tan, AG Bocobo, KH Lim, ... Clinical Cancer Research 25 (20), 6107-6118, 2019 | 81 | 2019 |
